The Technical Analyst
Impel Pharmaceuticals [IMPL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Impel Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-27.27% $0.0400
America/New_York / 20 des 2023 @ 15:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.956 mill |
| EPS: | -3.12 |
| P/E: | -0.0128 |
| Earnings Date: | N/A |
| SharesOutstanding: | 23.90 mill |
| Avg Daily Volume: | 1.024 mill |
| RATING 2024-01-16 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0128 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0128 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0149 - 0.217 ( +/- 114.74%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-18 | Smith Brandon D | Buy | 0 | |
| 2023-12-15 | Vivo Capital Viii, Llc | Sell | 87 934 | Common Stock |
| 2023-12-18 | Vivo Capital Viii, Llc | Sell | 209 029 | Common Stock |
| 2023-12-19 | Vivo Capital Viii, Llc | Sell | 208 657 | Common Stock |
| 2023-12-15 | Vivo Capital Viii, Llc | Sell | 12 066 | Common Stock |
| INSIDER POWER |
|---|
| 47.51 |
| Last 95 transactions |
| Buy: 8 739 782 | Sell: 5 181 184 |
Forecast:
01:40 - $0.169
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0400 (-27.27% ) |
| Volume | 0.720 mill |
| Avg. Vol. | 1.024 mill |
| % of Avg. Vol | 70.32 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IMPL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IMPL
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Last 10 Buy Signals
Latest Press Releases
2023-12-19 23:10:00 - Press Release
Impel Pharmaceuticals Announces Filing Of Voluntary Chapter 11 Cases And Signing Of "stalking Horse" Agreement To Facilitate Sale
Patient access to trudhesa® to continue uninterrupted sufficient liquidity to fund day to day operations during court-supervised process seattle , dec. 19, 2023 /prnewswire/ -- impel pharmaceuticals inc. (otcqx: impl) ("impel" or "the company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the company and has entered into an agreement with jn bidco llc to serve as the "stalking horse" bidder to acquire the company and its assets. to facilitate an orderly sale process, the company has filed voluntary petitions to commence chapter 11 proceedings in the u...
2023-06-15 08:00:00 - Press Release
Impel Pharmaceuticals To Present New Real-world Data For Trudhesa® At The 65th Annual Scientific Meeting Of The American Headache Society
Real-world assessment suggests that concomitant preventive and acute medication use decreases in patients using trudhesa
2023-05-05 08:00:00 - Press Release
Impel Pharmaceuticals To Report First Quarter 2023 Financial Results On Friday, May 12, 2023
Seattle, may 05, 2023 (globe newswire) -- impel pharmaceuticals inc. (nasdaq: impl), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on friday, may 12, 2023, at 8:30 a.m. et to report its first quarter 2023 financial results and provide a business update.
2023-03-17 08:00:00 - Press Release
Impel Pharmaceuticals To Report Fourth Quarter And Full Year 2022 Financial Results On Friday, March 24, 2023
Seattle, march 17, 2023 (globe newswire) -- impel pharmaceuticals inc. (nasdaq: impl), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on friday, march 24, 2023, at 8:30 a.m. et to report its fourth quarter and full year 2022 financial results and provide a business update.
2023-03-03 16:01:00 - Press Release
Impel Pharmaceuticals To Participate In Upcoming Investor Conferences In March
Seattle, march 03, 2023 (globe newswire) -- impel pharmaceuticals inc. (nasdaq: impl), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the company will participate in two upcoming investor conferences in march:
Latest News
2023-09-08 08:14:53 - InvestorPlace
Why Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?
Impel Pharmaceuticals (NASDAQ: IMPL ) stock is on the rise Friday after the company announced an amended credit agreement with Oaktree Fund Administration. This new credit agreement has Impel Pharmaceuticals obtaining a loan of $121.5 million from new and existing investors.
2023-08-16 08:50:03 - InvestorPlace
Why Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?
Impel Pharmaceuticals (NASDAQ: IMPL ) stock is falling on Wednesday after the biopharmaceutical company failed to file its earnings report on time. According to a filing with the Securities and Exchange Commission (SEC), several issues kept Impel Pharmaceuticals from filing in a timely manner.
2023-06-15 08:00:00 - GlobeNewsWire
Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society
Real-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa
2023-05-05 08:00:00 - GlobeNewsWire
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update.
2023-03-24 15:20:02 - Seeking Alpha
Impel Pharmaceuticals Inc. (IMPL) Q4 2022 Earnings Call Transcript
Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q4 2022 Earnings Conference Call March 24, 2023 8:30 AM ET Company Participants Adrian Adams - Chairman & Chief Executive Officer Leonard Paolillo - Chief Commercial Officer Rajiv Amin - Controller & Interim Chief Financial Officer Conference Call Participants Stacy Ku - Cowen Eddie Hickman - Guggenheim Partners Laura Chico - Wedbush Sean Kim - JonesTrading Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings and Business Update Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.
2023-03-24 11:27:19 - Zacks Investment Research
Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates
Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 6.73% and 23.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2023-03-17 08:00:00 - GlobeNewsWire
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24, 2023, at 8:30 a.m. ET to report its fourth quarter and full year 2022 financial results and provide a business update.
2023-03-03 16:01:00 - GlobeNewsWire
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Company will participate in two upcoming investor conferences in March:
2022-11-14 13:24:05 - Seeking Alpha
Impel Pharmaceuticals Inc. (IMPL) Q3 2022 Earnings Call Transcript
Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q3 2022 Results Conference Call November 14, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Operator Good morning, ladies and gentlemen, and welcome to Impel Pharmaceuticals Third Quarter 2022 Earnings and Business Update Conference Call. At this time, all participants are in a listen-only mode.
2022-08-15 10:33:07 - Seeking Alpha
Impel Pharmaceuticals, Inc. (IMPL) CEO Adrian Adams on Q2 2022 Results - Earnings Call Transcript
Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard S. Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Laura Chico - Wedbush Eddie Hickman - Guggenheim Securities Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals' Second Quarter 2022 Earnings and Business Update Conference Call.